|
| Tuesday, December 2, 2014 |
|
|
Cytokinetics Announces Presentations Relating to Tirasemtiv at the 25th International Symposium on ALS/MND |
| Cytokinetics (Nasdaq: CYTK) announced today that presentations relating to tirasemtiv are scheduled during the 25th International Symposium on ALS/MND to be held December 5-7, 2014 at the Square Brussels Meeting Centre in Brussels, Belgium. more info >> |
|
| Thursday, November 27, 2014 |
|
|
Cytokinetics to Participate in the 26th Annual Piper Jaffray Healthcare Conference |
| Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that Robert I. Blum, President and Chief Executive Officer, is scheduled to participate in a panel presentation during the upcoming 26th Annual Piper Jaffray Healthcare Conference. more info >> |
|
| Tuesday, November 11, 2014 |
|
|
Cytokinetics' President & CEO Robert Blum Receives 2014 Lou Gehrig Iron Horse Award From ALS Therapy Development Institute |
| Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that the Company's President and CEO, Robert Blum, received the 2014 Lou Gehrig Iron Horse Award from ALS Therapy Development Institute (ALS.net) at the Fourth Annual A White Coat Affair Gala on Saturday, November 8, 2014. more info >> |
|
| Friday, October 31, 2014 |
|
|
Cytokinetics, Incorporated Reports Third Quarter 2014 Financial Results |
| Cytokinetics, Incorporated (Nasdaq: CYTK) reported total research and development revenues for the third quarter of 2014 were $9.4 million, compared to $4.5 million during the same period in 2013. more info >> |
|
| Tuesday, October 28, 2014 |
|
|
Cytokinetics Provides Development Program Update for Omecamtiv Mecarbil |
| Cytokinetics, Incorporated (Nasdaq: CYTK) provided an update today relating to omecamtiv mecarbil, the company's lead drug candidate from its cardiac muscle contractility program. more info >> |
|
| Tuesday, October 21, 2014 |
|
|
Cytokinetics Provides Development Program Update for Tirasemtiv |
| Cytokinetics, Incorporated (Nasdaq: CYTK) provided a program update today relating to tirasemtiv, the company's lead drug candidate from its skeletal muscle contractility program. more info >> |
|
| Friday, October 17, 2014 |
|
|
Cytokinetics to Announce Third Quarter Results on October 30, 2014 |
| Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that it is scheduled to report third quarter results on Thursday, October 30, 2014 at 4:00 PM Eastern Time. more info >> |
|
| Tuesday, October 14, 2014 |
|
|
Cytokinetics Announces Development Program Update for CK-2127107 |
| Cytokinetics, Incorporated (Nasdaq: CYTK) announced the completion of five Phase I clinical trials evaluating CK-2127107 in healthy volunteers, and certain other Phase II readiness activities, all in connection with the agreed development plan under the collaboration between Cytokinetics and Astellas Pharma Inc. more info >> |
|
| Friday, August 8, 2014 |
|
|
Cytokinetics to Present at the 34th Annual Canaccord Global Growth Conference |
| Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that Robert I. Blum, President and Chief Executive Officer, is scheduled to present a corporate update at the 34th Annual Canaccord Global Health Conference on August 14, 2014 at 10:30 AM Eastern time at the Intercontinental Hotel in Boston, MA. more info >> |
|
| Thursday, July 31, 2014 |
|
|
Cytokinetics, Incorporated Reports Second Quarter 2014 Financial Results |
| Cytokinetics, Incorporated (Nasdaq: CYTK) reported total research and development revenues for the second quarter of 2014 were $7.8 million, compared to $1.0 million during the same period in 2013. more info >> |
|
|
|
|
